In a clinical study, Control-IQ technology significantly improved time in range.*

In the National Institutes of Health-funded Diabetes Closed Loop Trial, Protocol 3, time in range* for participants using a t:slim X2™ insulin pump with Control-IQ™ technology for six months averaged 71% per day compared to 59% for sensor-augmented pump therapy alone.1

View clinical evidence

71%

Time in range* per day (24 hours) for study participants using Control-IQ technology on the t:slim X2 pump.1

76%

Overnight time in range (00:00-06:00)* for study participants using Control-IQ technology.1

For users who aren’t hitting HbA1c targets, the t:slim X2 pump with Control-IQ technology can help.

Struggles with glucose control impact loved ones, caregivers, and even coworkers. Our easy-to-use t:slim X2 insulin pump with Control-IQ technology helps users achieve targets, and better glucose management means happier users. Regardless of baseline A1c, most study participants had a reduction over the 6‑month pivotal trial.1

How does Control-IQ technology work?

Control-IQ technology helps increase time in range* using Dexcom G6 continuous glucose monitoring (CGM, sold separately) values to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly, including delivery of automatic correction boluses as needed.

Illustration of How Control-IQ Works

Smooth Basal Rate Attenuation

Control-IQ technology smoothly decreases or discontinues basal delivery based on falling CGM values to help prevent hypoglycemia.

Control-IQ Technology Decreasing Basal

Automatic Correction Boluses

Control-IQ technology gradually increases basal insulin with increasing CGM values and administers 60% correction boluses once an hour as needed to help prevent hyperglycemia.

Control-IQ Technology Auto Bolus

Sleep and Exercise Activity Settings

Control-IQ technology includes optional settings for Sleep Activity and Exercise Activity that adjust treatment ranges to better match physiologic needs when active or sleeping.

Control-IQ Technology Sleep Activity

Control-IQ technology offers a variety of features designed to help make control easier for people living with diabetes.

Automatic Basal Insulin Adjustments

Control-IQ technology automatically adjusts insulin levels based on Dexcom G6 CGM readings. The system uses a predictive algorithm to minimize wide fluctuations in glucose levels, increasing time in range.* In studies, the system was available 92% of the time.1

Automatic Correction Boluses

Control-IQ technology can deliver automatic correction boluses, a first for automated insulin dosing devices.

High Usability Ratings From Patients

On a 5-point scale, with 5 representing the optimal score, study participants rated the t:slim X2 insulin pump with Control-IQ technology a 4.8 for desire to continue use of the system, 4.7 for ease of use, and 4.5 for trust.2

Improved HbA1c and Mean Glucose

For people struggling with glucose control, using Control-IQ technology may be able to help them more easily achieve their targets. Study participants using Control-IQ technology saw statistically significant improvements in HbA1c and mean glucose values.1

Decreased Hyperglycemia

Time spent with glucose values above 10.0 mmol/L was only 27% in those using the t:slim X2 insulin pump with Control-IQ technology compared to 39% in the control group.1

Zero Fingersticks

When the t:slim X2 pump is integrated with Dexcom G6 CGM, zero fingersticks are required for calibration or mealtime dosing.

 
 
Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Responsible Use of Control-IQ Technology

Even with advanced systems such as the t:slim X2 insulin pump with Control-IQ technology, users are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that users accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Since there are situations and emergencies that the system may not be capable of identifying or addressing, users should always pay attention to their symptoms and treat accordingly.

* As measured by CGM.
† If glucose values are predicted to be above 10.0 mmol/L, Control-IQ technology calculates a correction bolus with a target of 6.1 mmol/L and delivers 60% of that value. It will do this up to once per hour as needed.
‡ Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 CGM integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

References:
1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-17. DOI: 10.1056/NEJMoa1907863
2. Brown S. Clinical Acceptance of the Artificial Pancreas: Glycemia outcomes from a 6-month multicenter RCT. Poster presented at 79th Scientific Sessions of the American Diabetes Association; June 7-11, 2019; San Francisco, CA.

 

Important Safety Information

The t:slim X2 insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to automatically increase, decrease, and suspend delivery of basal insulin based on CGM sensor readings and predicted glucose values. The System can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The pump and the System are indicated for use in individuals six years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, or Humalog U-100 insulin. The System is intended for the management of Type 1 diabetes.

WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in users who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

 
The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Do not use the System if using hydroxyurea. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.